NephroGenex, Inc.: Chapter 11 case summary
ElevenFlo ·
NephroGenex’s Chapter 11 case ended with a final decree closing the case on November 20, 2017, after its reorganization plan became effective in May 2017. The final decree Dkt. 506 also approved the final report and accounting; no further case milestone is identified.
NephroGenex, Inc.’s Chapter 11 case, filed on April 20, 2016, was closed by final decree Dkt. 506 on November 20, 2017. The court confirmed the debtor’s plan on May 10, 2017, and the effectiveness notice Dkt. 442 reported that the plan became effective and was substantially consummated on May 25, 2017.
At filing, NephroGenex reported approximately $6.2 million in unsecured liabilities, largely trade debt associated with winding down its clinical programs. Its first-day declaration Dkt. 4 stated that the company had repaid its term loan, interest and end-of-term fee for approximately $6.3 million in February 2016 and had no secured debt at the petition date. No prepetition funded debt was reported.
Sources
- Dkt. 4First Day DeclarationFiled Apr 30, 2016Apr 30, 2016
- Dkt. 442Notice of (A) Entry of Order Confirming Plan of Reorganization Pursuant to Chapter 11 of the Bankruptcy Code Proposed by the Debtor; (B) Effective Date of the Plan; (C) Substantial Consummation of the Plan; and (D) Bar Dates for Certain Administrative, Professional Fee and Rejection Damages ClaimsFiled May 25, 2017May 25, 2017
- Dkt. 506Order and Final Decree (I) Closing Chapter 11 Case, (II) Approving Final Report and Accounting, (III) Terminating Engagement of Kurtzman Carson Consultants LLC and (IV) Granting Related ReliefFiled Nov 20, 2017Nov 20, 2017